Drug · DIN 01926799
IMOVANE
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since June 13, 2006; first marketed December 31, 1990.
- Drug Identification Number (DIN)
- 01926799
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Zopiclone N05CF01
- Class
- Human
- Record last updated
- June 15, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ZOPICLONE | 7.5 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- April 18, 2006: NOC 7886New Drug Submission (NDS) · Manufacturer name change
- October 5, 2000: NOC 1497New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “imovane”. A notice may cover another product or only some lots: read it to see what it covers.
- IMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For Health ProfessionalsNovember 19, 2014 · Drugs · Product safety
- IMOVANE (zopiclone) - New Dosage Recommendations to Minimize the Risk of Next-Day Impairment - For the PublicNovember 19, 2014 · Drugs · Product safety
Other DINs named IMOVANE
- DIN 02216167 · Cancelled Post Market